Magenta Therapeutics

OverviewSuggest Edit

Magenta’s mission is to revolutionize stem cell transplant as the treatment for immune and blood diseases. Stem cell transplant is a curative approach for a variety of severe blood cancers but is seldom used outside of cancer due to toxicities associated with the transplant procedure. Recent clinical data show that stem cell transplant can cure patients suffering from sickle cell disease, inherited metabolic disorders and severe autoimmune diseases. By developing safer and more effective therapeutics for conditioning, next generation products for stem cell mobilization and novel therapeutics for stem cell expansion, Magenta’s products will enable more patients to access the curative power of HSCT.
TypePublic
Founded2016
HQCambridge, US
Websitemagentatx.com

Latest Updates

Employees (est.) (Mar 2019)62(+6%)
Share Price (Oct 2019)$10 (+3%)

Key People/Management at Magenta Therapeutics

Bastiano Sanna

Bastiano Sanna

COO
Michael Cooke

Michael Cooke

Chief Scientific Officer
Christina Isacson

Christina Isacson

VP and Head of Business Development
Jason Gardner

Jason Gardner

Chief Executive Officer, President and Cofounder
Show more

Magenta Therapeutics Office Locations

Magenta Therapeutics has an office in Cambridge
Cambridge, US (HQ)
50 Hampshire St
Show all (1)

Magenta Therapeutics Financials and Metrics

Magenta Therapeutics Revenue

USD

Net income (Q2, 2019)

(17.7m)

EBIT (Q2, 2019)

(19.3m)

Market capitalization (15-Oct-2019)

387.7m

Closing stock price (15-Oct-2019)

10.0

Cash (30-Jun-2019)

33.1m
Magenta Therapeutics's current market capitalization is $387.7 m.
Annual
USDFY, 2018

General and administrative expense

18.6m

R&D expense

41.3m

Operating expense total

60.0m

EBIT

(60.0m)
Quarterly
USDQ1, 2019Q2, 2019

General and administrative expense

5.8m5.9m

R&D expense

10.5m13.4m

Operating expense total

16.4m19.3m

EBIT

(16.3m)(19.3m)
Annual
USDFY, 2018

Cash

58.3m

Current Assets

145.3m

PP&E

10.2m

Total Assets

157.3m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

173.4m159.7m31.2m33.1m

Current Assets

175.9m162.9m135.1m183.0m

PP&E

2.9m8.1m10.6m10.6m

Total Assets

180.6m172.8m147.7m195.4m
Annual
USDFY, 2018

Net Income

(57.5m)

Depreciation and Amortization

875.0k

Accounts Payable

2.5m

Cash From Operating Activities

(41.9m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(24.8m)(40.8m)(14.8m)(32.5m)

Depreciation and Amortization

307.0k516.0k423.0k875.0k

Accounts Payable

995.0k2.1m(658.0k)(430.0k)

Cash From Operating Activities

(18.7m)(29.3m)(14.9m)(30.0m)
USDY, 2019

Financial Leverage

1.1 x
Show all financial metrics

Magenta Therapeutics Online and Social Media Presence

Embed Graph

Magenta Therapeutics News and Updates

Magenta Therapeutics Blogs

Magenta Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

-- Initiated Phase 1 study of MGTA-145 first-line mobilization therapy, enrollment on track for data presentation before end of year -- -- Presented updated Phase 2 clinical data on MGTA-456 cell therapy in patients with inherited metabolic disorders at American Academy of Neurology annual meeting

Magenta Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 13th

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2019-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Wedbush

Magenta Therapeutics Appoints Anne McGeorge to Board of Directors

Magenta Therapeutics: Manisha Pai, Vice President, Communications & Investor Relations 617-510-9193 mpai@magentatx.com

Magenta Therapeutics to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 6, 2019-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that the Company is scheduled to present at the Goldman

Magenta Therapeutics Frequently Asked Questions

  • When was Magenta Therapeutics founded?

    Magenta Therapeutics was founded in 2016.

  • Who are Magenta Therapeutics key executives?

    Magenta Therapeutics's key executives are Bastiano Sanna, Michael Cooke and Christina Isacson.

  • How many employees does Magenta Therapeutics have?

    Magenta Therapeutics has 62 employees.

  • Who are Magenta Therapeutics competitors?

    Competitors of Magenta Therapeutics include PacifiCord, Clementia Pharmaceuticals and DBV Technologies.

  • Where is Magenta Therapeutics headquarters?

    Magenta Therapeutics headquarters is located at 50 Hampshire St, Cambridge.

  • Where are Magenta Therapeutics offices?

    Magenta Therapeutics has an office in Cambridge.

  • How many offices does Magenta Therapeutics have?

    Magenta Therapeutics has 1 office.